Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 3, 2005, Pages 277-281

  Gonin, Joyce M ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Endothelium; Folate; Homocysteine; Uraemia

Indexed keywords

DNA; FOLIC ACID; HOMOCYSTEINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIET SUPPLEMENTATION; DNA METHYLATION; GENE EXPRESSION; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MALNUTRITION; METABOLISM; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; UREMIA; VASCULAR ENDOTHELIUM;

EID: 18844447988     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000165896.98372.f4     Document Type: Review

References (52)

1. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidative stress and hyperhomocysteinemia. Curr Opinion in Nephr Hypertens 2000; 9:477-487.
2. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62:1402-1407.
3. Moat SJ, Doshi SN, Lang D, et al. Treatment of coronary heart disease with folic acid: is there a future? Am J Physiol Heart Circ Physiol 2004; 287:H1-H7. This paper addresses the question of whether homocysteine is a risk factor for CVD or whether it is an epiphenomenon of vascular disease.
4. Danish J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5:229-232.
5. Francis ME, Egers PW, Hostetter TH, Briggs JP. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 2004; 66:303-312. This paper is the first large study to demonstrate that even moderate levels of kidney dysfunction are associated with hyperhomocysteindemia.
6. Buccianti G, Baragetti I, Bamonti F, et al. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004; 17:405-410. A recent study which supports earlier retrospective and prospective studies supporting a relationship between hyperhomocysteinemia and cardiovascular risk in renal disease.
7. Wrone EM, Hornberger JM, Zehnder JL, et al. Randomized trial of folic acid for the prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15:420-426. These authors suggest an inverse relationship between homocysteine and cardiovascular risk.
8. Kalantar-Zadeh, Block B, Humphreys MH, et al. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15:442-453. These authors suggest that the reason why homocysteine may be inversely related to cardiovascular risk is that homocysteine is a marker of nutrition.
9. Bostom AG, Selhub J, Jacques PF, et al. Power shortage: clinical trials testing the 'homocysteine hypothesis' against a background of folic acid-fortified cereal grain flour. Ann Intern Med 2001; 135:133-137.
10. Marucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 2003; 75:1551-1555.
11. Zoungas S, Branley P, Kerr PG, et al. Atherosclerosis and Folic Acid Supplementation Trial in chronic renal failure: baseline results. Nephrology 2004; 9:130-141.
12. Van Guldener C, Donker AJM, Jakobs C, Teerlink T. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54:166-169.
13. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52:495-502.
14. Perna AF, Ingrosso D, Satta E, et al. Homocysteine metabolism in renal failure. Curr Opin Clin Nutr Metab Care 2004; 7:53-57. This is an excellent review of current hypotheses to explain the hyperhomocysteinaemia seen in renal failure.
15. Wilcox CS. Hyperhomocyst(e)inemia in therapy in nephrology and hypertension. vol. 68. 2nd ed. London: Saunders; 2003. pp. 665-668.
16. Ghandour H, Bagley PJ, Shemin D, et al. Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid. Kidney Int 2002; 62:2246-2249.
17. Liu CS, Chiang HC, Chen HW. Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. Nutrition 2004; 20:974-978.
18. Sunder Plassman G, Födinger M, Buchmayer H, et al. Effect of high-dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna Multicenter study. J Am Soc Nephrol 2000; 11:1106-1116.
19. Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997; 95:1119-1121.
20. Nappo F, De Rosa N, De Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281:2113-2118.
21. Van Guldener C, Janssen MJFM, Lambert J, et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in hemodialysis patient. Nephrol Dial Transplant 1998; 13:106-112.
22. Chambers JC, McGregor A, Jean Marie J, et al. Demonstrations of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999; 99:1156-1160.
23. De Bree A, Verschuren WMM, Kromhout D, et al. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary artery disease. Pharmacol Rev 2002; 54:599-618.
24. Upchurch GR, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272:17012-17017.
25. Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteindemia in patients with uraemia. Lancet 2003; 361:1693-1699.
26. Gonella M, Calabrese G, Mengozzi A, et al. The achievement of normal homocysteinemia in regular extracorporeal dialysis patients. J Nephrol 2004; 17:411-413.
27. 6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol 2003; 16:522-534.
28. Righetti M, Ferrario G, Milani S, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. MedSciMonit 2003; 9:137-142.
29. De Vecchi AF, Novembrino C, Patrosso MC, et al. Effect of incremental doses of folate on homocysteine and metabolically related vitamin concentrations in nondiabetic patients on peritoneal dialysis. ASAIO J 2003; 49:655-659.
30. Touam M, Zingraff J, Jungers P, et al. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999; 56:2292-2296.
31. Bostom A, Shemin D, Bagley P, et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocyst(e)inemia in hemodialysis patients. Circulation 2000; 101:2829-2832.
32. Yango A, Shemin D, Hsu N, et al. L-folinic versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients [rapid communication]. Kidney Int 2001; 59:324-327.
33. Thanbyrajah J, Landray MJ, McGlynn FJ, et al. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure. Circulation 2002; 102:871-875.
34. Jungers P, Joly D, Massy Z, et al. Sustained reduction of hyperhomocysteindemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 1999; 14:2903-2906.
35. Chauveau P, Chadefaux B, Coude M, et al. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine in chronic renal failure. Miner Electrolyte Metab 1996; 22:106-109.
36. House AA, Wells GA, Donnelly JG, et al. Randomized trial of high-flux vs low-flux hemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000; 15:1029-1034.
37. Van Tellingen A, Grooteman MP, Bartels PC, et al. Long-term reduction of plasma homocysteine levels by supra-flux dialyzers in hemodialysis patients. Kidney Int 2001; 59:342-347.
38. Friedman AN, Bostom AG, Levey AS, et al. Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. J Am Soc Nephrol 2002; 13:265-268.
39. Woo KS, Chook P, Lolin YI, et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96:2542-2544.
40. Title LM, Cummings PM, Giddens K, et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000; 36:758-765.
41. Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102:2479-2483.
42. Guo H, Lee JD, Xing Y, et al. Changes of homocysteine levels and arterial endothelial function in patients with high risk of coronary artery disease after 6-month folic acid supplementation. Acta Cardiol 2004; 59:503-506.
43. Woodman RJ, Celermajer DE, Thompson PL, Hung J. Folic acid does not improve endothelial function in healthy hyperhomocystindemic subjects. Clin Sci 2004; 106:353-358.
44. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002; 105:22-26.
45. Stroes ES, Van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86:1129-1134.
46. Van Guldener C, Janssen MJ, Lambert J, et al. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 1998; 18:282-289.
47. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000; 83:205-209.
48. Hausberg M, Kisters K, Kosch M, et al. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int 1999; 55:1104-1110.
49. Kunz K, Petitjean P, Lisri M, et al. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Nephrol Dial Transplant 1999; 14:1934-1942.
50. Van Guldener C, Janssen MJ, Lambert J, et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13:106-112.
51. Van Guldener C, Janssen MJ, Lambert J, et al. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 1998; 18:282-289.
52. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Does folic acid decrease homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000; 102:871-875.